Cargando…

A pan‐genotype hepatitis C virus viral vector vaccine generates T cells and neutralizing antibodies in mice

BACKGROUND AND AIMS: A prophylactic vaccine targeting multiple HCV genotypes (gt) is urgently required to meet World Health Organization elimination targets. Neutralizing antibodies (nAbs) and CD4(+) and CD8(+) T cells are associated with spontaneous clearance of HCV, and each may contribute to prot...

Descripción completa

Detalles Bibliográficos
Autores principales:	Donnison, Timothy, McGregor, Joey, Chinnakannan, Senthil, Hutchings, Claire, Center, Rob J., Poumbourios, Pantelis, Klenerman, Paul, Drummer, Heidi E., Barnes, Eleanor
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9790311/ https://www.ncbi.nlm.nih.gov/pubmed/35313015 http://dx.doi.org/10.1002/hep.32470

Ejemplares similares

Enhancing the antigenicity and immunogenicity of monomeric forms of hepatitis C virus E2 for use as a preventive vaccine
por: Center, Rob J., et al.
Publicado: (2020)

The generation of a simian adenoviral vectored HCV vaccine encoding genetically conserved gene segments to target multiple HCV genotypes
por: von Delft, Annette, et al.
Publicado: (2018)

Virus-Like Particles Containing the E2 Core Domain of Hepatitis C Virus Generate Broadly Neutralizing Antibodies in Guinea Pigs
por: McGregor, Joey, et al.
Publicado: (2022)

The Design and Development of a Multi-HBV Antigen Encoded in Chimpanzee Adenoviral and Modified Vaccinia Ankara Viral Vectors; A Novel Therapeutic Vaccine Strategy against HBV
por: Chinnakannan, Senthil K., et al.
Publicado: (2020)

The core domain of hepatitis C virus glycoprotein E2 generates potent cross‐neutralizing antibodies in guinea pigs
por: Vietheer, Patricia T., et al.
Publicado: (2017)

Divergent memory responses driven by adenoviral vectors are impacted by epitope competition
por: Colston, Julia M, et al.
Publicado: (2019)

Hepatitis C Virus (HCV) Envelope Glycoproteins E1 and E2 Contain Reduced Cysteine Residues Essential for Virus Entry
por: Fraser, Johanna, et al.
Publicado: (2011)

Escape of Hepatitis C Virus from Epitope I Neutralization Increases Sensitivity of Other Neutralization Epitopes
por: Gu, Jun, et al.
Publicado: (2018)

Conjugation of an scFab domain to the oligomeric HIV envelope protein for use in immune targeting
por: King, Hannah A. D., et al.
Publicado: (2019)

Allosteric Modulation of the HIV-1 gp120-gp41 Association Site by Adjacent gp120 Variable Region 1 (V1) N-Glycans Linked to Neutralization Sensitivity
por: Drummer, Heidi E., et al.
Publicado: (2013)

Longitudinal Sequence and Functional Evolution within Glycoprotein E2 in Hepatitis C Virus Genotype 3a Infection
por: Alhammad, Yousef M. O., et al.
Publicado: (2015)

To Include or Occlude: Rational Engineering of HCV Vaccines for Humoral Immunity
por: Schlotthauer, Felicia, et al.
Publicado: (2021)

Enhanced stability of the SARS CoV-2 spike glycoprotein following modification of an alanine cavity in the protein core
por: Poumbourios, Pantelis, et al.
Publicado: (2023)

Use of an Outbred Rat Hepacivirus Challenge Model for Design and Evaluation of Efficacy of Different Immunization Strategies for Hepatitis C Virus
por: Atcheson, Erwan, et al.
Publicado: (2019)

Forced virus evolution reveals functional crosstalk between the disulfide bonded region and membrane proximal ectodomain region of HIV-1 gp41
por: Khasawneh, Ashraf I, et al.
Publicado: (2013)

Challenges to the development of vaccines to hepatitis C virus that elicit neutralizing antibodies
por: Drummer, Heidi E.
Publicado: (2014)

Monoclonal Antibodies Directed toward the Hepatitis C Virus Glycoprotein E2 Detect Antigenic Differences Modulated by the N-Terminal Hypervariable Region 1 (HVR1), HVR2, and Intergenotypic Variable Region
por: Alhammad, Yousef, et al.
Publicado: (2015)

HBV001: Phase I study evaluating the safety and immunogenicity of the therapeutic vaccine ChAdOx1-HBV
por: Cargill, Tamsin, et al.
Publicado: (2023)

Identification of Broad-Genotype HPV L2 Neutralization Site for Pan-HPV Vaccine Development by a Cross-Neutralizing Antibody
por: Wang, Daning, et al.
Publicado: (2015)

PanSNPdb: The Pan-Asian SNP Genotyping Database
por: Ngamphiw, Chumpol, et al.
Publicado: (2011)

An expanded taxonomy of hepatitis C virus genotype 6: Characterization of 22 new full-length viral genomes
por: Li, Chunhua, et al.
Publicado: (2015)

Morbillivirus V Proteins Exhibit Multiple Mechanisms to Block Type 1 and Type 2 Interferon Signalling Pathways
por: Chinnakannan, Senthil K., et al.
Publicado: (2013)

Characterizing Hepatitis C Virus–Specific CD4(+) T Cells Following Viral‐Vectored Vaccination, Directly Acting Antivirals, and Spontaneous Viral Cure
por: Hartnell, Felicity, et al.
Publicado: (2020)

Viral Vectors for the Induction of Broadly Neutralizing Antibodies against HIV
por: Wilmschen, Sarah, et al.
Publicado: (2019)

Investigation of IRES Insertion into the Genome of Recombinant MVA as a Translation Enhancer in the Context of Transcript Decapping
por: Alharbi, Naif Khalaf, et al.
Publicado: (2015)

A Fully Protective Congenital CMV Vaccine Requires Neutralizing Antibodies to Viral Pentamer and gB Glycoprotein Complexes but a pp65 T-Cell Response Is Not Necessary
por: Choi, K. Yeon, et al.
Publicado: (2021)

Interferon lambda 4 variant rs12979860 is not associated with RAV NS5A Y93H in hepatitis C virus genotype 3a
por: Pedergnana, Vincent, et al.
Publicado: (2016)

Viral dynamics among HCV infected patients with different genotypes treated with genotypic specific or pan-genotypic direct-acting antiviral agent combinations
por: Paolucci, Stefania, et al.
Publicado: (2019)

HCV genotype-3a T cell immunity: specificity, function and impact of therapy
por: Humphreys, Isla S, et al.
Publicado: (2012)

Interferon lambdas: the next cytokine storm
por: Kelly, Christabel, et al.
Publicado: (2011)

Ever closer to a prophylactic vaccine for HCV
por: Swadling, Leo, et al.
Publicado: (2013)

Different functions of the common P/V/W and V-specific domains of rinderpest virus V protein in blocking IFN signalling
por: Chinnakannan, Senthil K., et al.
Publicado: (2014)

New neutral vector bosons at HERA
por: Martyn, H U, et al.
Publicado: (1992)

The broad assessment of HCV genotypes 1 and 3 antigenic targets reveals limited cross-reactivity with implications for vaccine design
por: von Delft, Annette, et al.
Publicado: (2016)

Induction and Maintenance of CX3CR1-Intermediate Peripheral Memory CD8(+) T Cells by Persistent Viruses and Vaccines
por: Gordon, Claire Louse, et al.
Publicado: (2018)

Impact of Interferon Lambda 4 Genotype on Interferon‐Stimulated Gene Expression During Direct‐Acting Antiviral Therapy for Hepatitis C
por: Ramamurthy, Narayan, et al.
Publicado: (2018)

A Novel Murine Cytomegalovirus Vaccine Vector Protects against Mycobacterium tuberculosis
por: Beverley, Peter C. L., et al.
Publicado: (2014)

Discovery and characterization of a neutralizing pan-ELR+CXC chemokine monoclonal antibody
por: Boyles, Jeffrey S., et al.
Publicado: (2020)

Engineering pan–HIV-1 neutralization potency through multispecific antibody avidity
por: Rujas, Edurne, et al.
Publicado: (2022)

Structural definition of a pan-sarbecovirus neutralizing epitope on the spike S2 subunit
por: Hurlburt, Nicholas K., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_651hein7e585stu5dopvokddcp